These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 31724165)
1. Comparing the efficacy, exposure, and cost of clinical trial analysis methods. Oliveira A; Romero JM; Goldenholz DM Epilepsia; 2019 Dec; 60(12):e128-e132. PubMed ID: 31724165 [TBL] [Abstract][Full Text] [Related]
2. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Heaney DC; Shorvon SD; Sander JW Epilepsia; 1998; 39 Suppl 3():S19-25. PubMed ID: 9593232 [TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Connock M; Frew E; Evans BW; Bryan S; Cummins C; Fry-Smith A; Li Wan Po A; Sandercock J Health Technol Assess; 2006 Mar; 10(7):iii, ix-118. PubMed ID: 16545206 [TBL] [Abstract][Full Text] [Related]
10. Evaluating dynamic treatment strategies: does it have to be more costly? Buyze J; Goetghebeur E Pharm Stat; 2013; 12(1):35-42. PubMed ID: 23208788 [TBL] [Abstract][Full Text] [Related]
11. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Chadwick D; Marson T Epilepsia; 2007 Jul; 48(7):1259-63. PubMed ID: 17442006 [TBL] [Abstract][Full Text] [Related]
12. A comparison of surgical and medical costs for refractory epilepsy. Platt M; Sperling MR Epilepsia; 2002; 43 Suppl 4():25-31. PubMed ID: 12059998 [No Abstract] [Full Text] [Related]
13. The pharmacoeconomics of the new antiepileptic drugs. Heaney D Epilepsia; 1999; 40 Suppl 8():25-31. PubMed ID: 10563592 [No Abstract] [Full Text] [Related]
14. Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy. Simoens S Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):309-15. PubMed ID: 20545595 [TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis for the use of serum antiepileptic drug level monitoring in children diagnosed with structural-metabolic epilepsy. Salih MR; Bahari MB; Shafie AA; Hassali MA; Al-Lela OQ; Abd AY; Ganesan VM Epilepsy Res; 2013 Mar; 104(1-2):151-7. PubMed ID: 23103061 [TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391 [TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL Value Health; 2007; 10(3):173-82. PubMed ID: 17532810 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. Verdian L; Yi Y Seizure; 2010 Jan; 19(1):1-11. PubMed ID: 19942457 [TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of epilepsy treatment: a review of the literature. Heaney DC; Begley CE Epilepsia; 2002; 43 Suppl 4():10-6. PubMed ID: 12059996 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]